Reuters logo
BRIEF-Sage Therapeutics says SAGE-547 achieves 77 pct response rate in Phase 1/2 trial
May 14, 2015 / 10:27 AM / 2 years ago

BRIEF-Sage Therapeutics says SAGE-547 achieves 77 pct response rate in Phase 1/2 trial

May 14 (Reuters) - Sage Therapeutics

* Sage-547 demonstrated robust activity, with 77 percent response rate in evaluable patients with super-refractory status epilepticus

* Overall, 64 percent of patients experienced at least 1 serious adverse event, none drug-related determined by safety review committee

* Phase 3 status trial expected to initiate by mid-2015 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below